However, because in previous studies the number of patients, the period of study and the examined cell populations were limited, it is not clear whether there is a key population of peripheral immune cells that attenuates RA clinical symptoms through anti-IL-6R therapies [11,12,15]. The gene discussed is IL6R; the disease is rheumatoid arthritis.